Somatrem

Summary

Somatrem (CHEMBL1201620) is an approved protein (ATC H01AC02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01AC02
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201620
Name	Somatrem
Type	Protein
Max phase	4
ATC	H01AC02

Also known as: Protropin, Protropin (genentech), Somatrem, SOMATREM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00097539	Not specified	COMPLETED	National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).